Literature DB >> 9248784

Variability of diphenhydramine N-glucuronidation in healthy subjects.

D Fischer1, U Breyer-Pfaff.   

Abstract

The H1-antagonist diphenhydramine can undergo direct glucuronidation at its tertiary amino group with formation of a quaternary ammonium glucuronide. The intraindividual variability in the amount of N-glucuronide excretion in urine was investigated in two female volunteers who repeatedly took single doses of 25 mg diphenhydramine hydrochloride without and with concomitant administration of ascorbic acid or ammonium chloride for urine acidification. Another two female and four male subjects underwent single tests without and with additional ascorbic acid. Diphenhydramine N-glucuronide quantities in urine differed significantly among subjects and ranged between 2.7% and 14.8% of the dose within 8 h. Neither ascorbic acid nor ammonium chloride significantly influenced the quantity of N-glucuronide in urine, but ammonium chloride, that in contrast to ascorbic acid proved effective in lowering urinary pH, increased the excretion of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9248784     DOI: 10.1007/BF03189799

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  Quaternary N-glucuronides of 10-hydroxylated amitriptyline metabolites in human urine.

Authors:  U Breyer-Pfaff; B Becher; E Nusser; K Nill; B Baier-Weber; D Zaunbrecher; H Wachsmuth; A Prox
Journal:  Xenobiotica       Date:  1990-07       Impact factor: 1.908

2.  Glucuronidation of amitriptyline in man in vivo.

Authors:  M L Dahl-Puustinen; A Aberg-Wistedt; L Bertilsson
Journal:  Pharmacol Toxicol       Date:  1989-07

3.  Identification of diphenydramine (Benadryl) metabolities in human subjects.

Authors:  T Chang; R A Okerholm; A J Glazko
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-11

4.  Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children.

Authors:  K J Simons; W T Watson; T J Martin; X Y Chen; F E Simons
Journal:  J Clin Pharmacol       Date:  1990-07       Impact factor: 3.126

5.  Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites.

Authors:  B Vandel; M Sandoz; S Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration.

Authors:  G T Blyden; D J Greenblatt; J M Scavone; R I Shader
Journal:  J Clin Pharmacol       Date:  1986 Sep-Oct       Impact factor: 3.126

7.  Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives.

Authors:  B G Luna; J M Scavone; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1989-03       Impact factor: 3.126

8.  Diphenhydramine in Orientals and Caucasians.

Authors:  R Spector; A K Choudhury; C K Chiang; M J Goldberg; M M Ghoneim
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

9.  Comparison of procedures for measuring the quaternary N-glucuronides of amitriptyline and diphenhydramine in human urine with and without hydrolysis.

Authors:  D Fischer; U Breyer-Pfaff
Journal:  J Pharm Pharmacol       Date:  1995-06       Impact factor: 3.765

10.  Synthesis and characterization of quaternary ammonium-linked glucuronide metabolites of drugs with an aliphatic tertiary amine group.

Authors:  H Luo; E M Hawes; G McKay; K K Midha
Journal:  J Pharm Sci       Date:  1992-11       Impact factor: 3.534

View more
  2 in total

1.  Case files of the medical toxicology fellowship at Drexel University. Rhabdomyolysis and compartment syndrome following acute diphenhydramine overdose.

Authors:  David Vearrier; John A Curtis
Journal:  J Med Toxicol       Date:  2011-09

2.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.